In a study of G-CSF (filgrastim) in patients with early breast cancer treated with epirubicin-cyclophosphamide chemotherapy, the rate of FN was 1% in the G-CSF arms compared with 7% in the control arms (P = .004) [7]. The gene discussed is CSF3; the disease is breast carcinoma.